Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer

PURPOSE: The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard of care therapy for metastatic non-small cell lung cancer (mNSCLC) has not been explored. EXPERIMENTAL DESIGN: A 500-gene next-generation sequencing (NGS) panel was used t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Aggarwal, Charu, Thompson, Jeffrey C., Chien, Austin L., Quinn, Katie J., Hwang, Wei-Ting, Black, Taylor A., Yee, Stephanie S., Christensen, Theresa E., LaRiviere, Michael J., Silva, Benjamin A., Banks, Kimberly C., Nagy, Rebecca J., Helman, Elena, Berman, Abigail T., Ciunci, Christine A., Singh, Aditi P., Wasser, Jeffrey S., Bauml, Joshua M., Langer, Corey J., Cohen, Roger B., Carpenter, Erica L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7231655/
https://ncbi.nlm.nih.gov/pubmed/32102950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3663
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados